Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The literature is inconclusive regarding the association between adherence and the number of concurrent prescribed medications. Among patients with type 2 diabetes (T2D), low medication adherence is linked with inadequate glycemic management and increased diabetes-related complications. Adherence to glucose-lowering, lipid-lowering, and antihypertensive medications may be impacted by the number of cardiometabolic medications taken by adults with T2D, including American Indian adults.

Objective: To examine the association between medication adherence and the number of cardiometabolic medications among American Indian adults with T2D using Tribal health services, a health care system where all medical care and medications are provided free of charge.

Methods: We used 2019 medication dispensing data and patient data from the electronic health records of the Choctaw Nation Health Services Authority. Our sample included 6,774 American Indian adults aged 20 years and older, previously diagnosed with T2D, who received at least 1 cardiometabolic medication from a Choctaw Nation Health Services Authority pharmacy. We measured medication adherence as the proportion of days covered (PDC; possible range 0-1). Analysis of variance and chi-square tests were used to examine the association between the number of medications and patient characteristics. Multiple linear regression was used to estimate the association of adherence with patient characteristics.

Results: The sample mean age was 58.4 (SD = 13.2) years; 63.4% were aged 55 years or older; 47.8% were male; 49.6% were single; 36.9% had comorbidities. 30.9% were prescribed 2 or fewer medications, 43.1% were prescribed greater than 2 to 4 medications, and 26.0% were prescribed more than 4 medications. 71.7% had noninsulin glucose-lowering medications, 68% had lipid-lowering medication, and 90% had antihypertensive medications. Overall, 60.6% of the sample were adherent (PDC ≥ 0.80), including 49% of those with 2 or fewer medications, 62% of those with greater than 2 to 4 medications, and 72% with more than 4 medications. In a multiple regression model, adherence was positively associated with the number of medications (b = 0.026,  < 0.001), age 55 years or older (b = 0.062,  < 0.001), male sex (b = 0.009,  = 0.046), and presence of comorbidities (b = 0.033,  < 0.001) but negatively associated with being single (b = -0.034,  < 0.001) and insulin usage (b = -0.019,  < 0.001).

Conclusions: To our knowledge, this is the first study demonstrating the association between a higher number of cardiometabolic medications and better adherence in American Indian adults diagnosed with T2D whose medications were provided without cost to the patients. Medication cost is a well-known medication adherence barrier. Future studies should further examine factors associated with nonadherence in this population, such as younger age and fewer medications.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123192PMC
http://dx.doi.org/10.18553/jmcp.2025.31.6.590DOI Listing

Publication Analysis

Top Keywords

medications
16
adherence number
12
number cardiometabolic
12
cardiometabolic medications
12
medication adherence
12
american indian
12
health services
12
adherence
8
patients type
8
type diabetes
8

Similar Publications

Spinal muscular atrophy (SMA) is a neuromuscular disease caused by low levels of SMN protein. Several therapeutic approaches boosting SMN are approved for human patients, delivering remarkable improvements in lifespan and symptoms. However, emerging phenotypes, including neurodevelopmental comorbidities, are being reported in some treated SMA patients, indicative of alterations in brain development.

View Article and Find Full Text PDF

Background: Active vitamin D metabolites, including 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D), have potent immunomodulatory effects that attenuate acute kidney injury (AKI) in animal models.

Methods: We conducted a phase 2, randomized, double-blind, multiple-dose, 3-arm clinical trial comparing oral calcifediol (25D), calcitriol (1,25D), and placebo among 150 critically ill adult patients at high-risk of moderate-to-severe AKI. The primary endpoint was a hierarchical composite of death, kidney replacement therapy (KRT), and kidney injury (baseline-adjusted mean change in serum creatinine), each assessed within 7 days following enrollment using a rank-based procedure.

View Article and Find Full Text PDF

Effect of knee joint position on soleus muscle function during isokinetic plantarflexion.

Physiol Int

September 2025

2Faculty of Sports Science, Ningbo University, No. 818 Fenghua Road, Jiangbei District, 315211, Ningbo City, Zhejiang Province, PR China.

Purpose: Contribution of the gastrocnemii muscles to ankle moment is influenced by the knee joint position because they span the knee and the ankle joint as well. However, limited information is available on the effect of knee joint position on soleus activation under dynamic plantarflexion, hence the aim of this study was to investigate if soleus have a compensatory strategy in fascicle behavior or EMG activity during knee flexed plantarflexion in order to reduce the magnitude of the decrement in ankle moment.

Equipment And Methods: Isokinetic dynamometry with EMG and ultrasound measurements was used to estimate medial gastrocnemius and soleus behavior during knee flexed and extended plantarflexions using three angular velocities.

View Article and Find Full Text PDF

Background: Experience with icodextrin use in children on long-term peritoneal dialysis is limited. We describe international icodextrin prescription practices and their impact on clinical outcomes: ultrafiltration, blood pressure control, residual kidney function (RKF), technique and patient survival.

Methods: We included patients under 21 years enrolled in the International Pediatric Peritoneal Dialysis Network (IPPN) between 2007 and 2024, on automated PD with a daytime dwell.

View Article and Find Full Text PDF

Background: Following SARS-CoV-2 infection, ~10-35% of COVID-19 patients experience long COVID (LC), in which debilitating symptoms persist for at least three months. Elucidating biologic underpinnings of LC could identify therapeutic opportunities.

Methods: We utilized machine learning methods on biologic analytes provided over 12-months after hospital discharge from >500 COVID-19 patients in the IMPACC cohort to identify a multi-omics "recovery factor", trained on patient-reported physical function survey scores.

View Article and Find Full Text PDF